MajesTEC-3: Redefining what’s possible in multiple myeloma

By Samer Al Hadidi, Mahmoud Gaballa. Despite these remarkable efficacy results, the safety profile warrants careful consideration. Grade 3 or 4 infections occurred in 54% of patients receiving teclistamab plus daratumumab, with 13 infection-related deaths.